Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT03639948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy. However, because TNBC is usually more aggressive, harder to treat, and more likely to come back, it is associated with poor long-term outcomes (survival rates) when compared to other types of breast cancer. Therefore, researchers are studying how new drugs and treatment combinations can improve the outcome of patients with TNBC. This study will test effectiveness of immune therapy (Pembrolizumab is an "immunotherapy" that is expected to work with the body's immune system to help fight cancer) in combination with chemotherapy given before surgery.
Study identification
- NCT ID
- NCT03639948
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 4, 2018 (Actual)
- Primary completion
- Jan 27, 2022 (Actual)
- Completion
- Nov 2024 (Estimated)
- Last update posted
- Apr 11, 2024
2018 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 3
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Kansas Cancer Center (KUCC) | Fairway | Kansas | 66205 | — |
| The University of Kansas Cancer Center, West Clinic | Kansas City | Kansas | 66112 | — |
| The University of Kansas Cancer Center, Westwood Campus | Kansas City | Kansas | 66205 | — |
| University of Kansas Cancer Center | Kansas City | Kansas | 66205 | — |
| The University of Kansas Cancer Center, Overland Park Clinic | Overland Park | Kansas | 66210 | — |
| The University of Kansas Cancer Center, North Clinic | Kansas City | Missouri | 64154 | — |
| The University of Kansas Cancer Center, Lee's Summit Clinic | Lee's Summit | Missouri | 64064 | — |
| The University of Kansas Medical Center | North Kansas City | Missouri | 64116 | — |
| Texas Oncology- Baylor | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03639948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03639948 live on ClinicalTrials.gov.